

Cover Story
FreeHealth Equity
By Matthew Bin Han Ong
FDA watchers and clinical trialists in oncology may want to pay close attention to the agency’s latest plans to increase representation of traditionally marginalized populations in drug development.
In Brief


Clinical Roundup


Trending Stories
- Anthony G. Letai to be named NCI director
The Dana-Farber and Harvard physician-scientist is an inspired choice, colleagues say - Trump’s FDA invents an unusual regulatory pathway to approve leucovorin for autism
Experts call the move “extremely premature” - NCI releases names of members of ad hoc working group—filling the void left by BSA
- Bhattacharya: New grant review criterion is “not political”
- ACOG says it will no longer accept federal funding
- Congress seems to have NCI’s back—is cautious optimism warranted? Two former directors say yes.